Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Vaccine_component
|
| gptkbp:administeredBy |
gptkb:Injection
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:contains |
Filamentous hemagglutinin
Fimbriae Pertactin Pertussis toxoid |
| gptkbp:introducedIn |
1990s
|
| gptkbp:lessLikelyToCause |
Severe adverse reactions
|
| gptkbp:prevention |
gptkb:Pertussis
|
| gptkbp:recommendation |
Adults
Children Infants Adolescents |
| gptkbp:replacedBy |
Whole-cell pertussis
|
| gptkbp:sideEffect |
Fever
Swelling at injection site Redness at injection site |
| gptkbp:usedIn |
gptkb:DTaP_vaccine
gptkb:Tdap_vaccine |
| gptkbp:bfsParent |
gptkb:Tetanus_Vaccine
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Acellular pertussis
|